Pacira BioSciences enters the final stretch before its June 9 earnings with a notable split: the stock has bounced sharply while shorts have barely budged.
The price action this week is the sharpest divergence in months. PCRX gained 9.2% over the past five sessions to close at $24.36, adding 4.3% on Tuesday alone. That recovery looks meaningful against a one-month backdrop that remains slightly negative, down 0.6%, suggesting the week's move is a genuine re-engagement from buyers rather than a simple continuation of prior momentum. The tension is that short sellers — who have held a heavy position for months — have not blinked.
Short interest tells a story of conviction on both sides. At 23.4% of the free float, the short position is substantial and has been remarkably sticky. When shorts spiked to 24.2% in late April, they only drifted back modestly before settling near current levels. The week's change is effectively flat — up just 0.4% in shares — meaning this week's price gain was absorbed without any meaningful short covering. The ORTEX short score holds at 72.7, near the top of its recent range, reinforcing that the overall positioning backdrop remains bearish. Borrow conditions, however, offer no particular urgency for either side: cost to borrow is just 0.54% annually, and availability is wide at 280% of short interest — plenty of room for new shorts to enter at minimal cost if they choose.
Options lean modestly more cautious than usual, but the signal is faint. The put/call ratio ticked up to 0.35 from its recent lows closer to 0.21-0.23 in early May, nudging slightly above its 20-day average of 0.31. At 0.68 standard deviations above the mean, this is a directional lean rather than a defensive stampede — the 52-week high on the PCR runs to 0.96, so current hedging is nowhere near extreme. The options market looks like a soft hedge rather than a hard bearish bet.
The Street is cautious but not hostile. The two most recent analyst moves, both on May 1, told slightly different stories: Needham lifted its target to $32 with a Buy, while RBC Capital raised to $24 while staying at Sector Perform — essentially flagging fair value at the current price. Both targets were raised after Q4 results, suggesting the print was good enough to push floors higher even if it didn't generate enthusiasm. The mean consensus price target of $29.29 implies roughly 20% upside from here. The bull case centers on EXPAREL's non-opioid positioning, pipeline depth around PCRX-201, and improving forward EPS momentum — the 12-month forward EPS growth factor ranks in the 97th percentile. The bear case is narrower but pointed: EXPAREL growth has been slower than the market wants, and the company has spent heavily on buybacks while revenue trajectory has underwhelmed.
Insiders have been net sellers. The CFO sold approximately $628,000 in shares across four transactions between April 20-23, near prices of $25.01-25.16 — marginally above the current level. CEO Frank Lee sold $852,000 in late January at $20.54. Over the past 90 days the insider net balance clocks in at roughly $2.6 million in sales. These are routine-sized transactions rather than panic-selling, but the direction is consistent: every named trade in the log is a sale.
Earnings on June 9 sharpen the focus. The last two prints both produced negative one-day moves — down 3.1% and 2.8% respectively — and each time the weakness extended over the following week, with five-day losses of 9.2% and 6.0%. The stock is now about 20% below the CFO's recent sale prices, which removes some of the overhang anxiety, but the pattern of post-earnings selling is well established. How EXPAREL's quarterly growth trajectory lands on June 9, against a backdrop of heavy short interest that has refused to cover even as the stock rallied, is the data point that will resolve the current stand-off.
See the live data behind this article on ORTEX.
Open PCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
